|
|
About
Us
ImmunoGenetix
Therapeutics, Inc. is a for-profit company developing advanced
DNA-based therapies. All communications with ImmunoGenetix Therapeutics
may be directed to:
ImmunoGenetix
Therapeutics
8527 Bluejacket Street
Lenexa, KS 66214 |
![[ Yahoo! Maps ]](http://us.i1.yimg.com/us.yimg.com/i/us/mp/gr/mplogo.gif)
|
(888) 7-IGXBIO toll free
(888) 744-9246 fax
James B. Laufenberg, President and CEO
jbl@igxbio.com
- Executive
Summary
- Board
of Directors
- Scientific
Advisory Board
- Scientific Collaboration
 Executive Summary
ImmunoGenetix
Therapeutics, Inc. is a biotechnology company developing advanced DNA
immunotherapies for HIV infection. The Company’s lead product
candidate, GenePro™, is a DNA therapeutic incorporating a proprietary
DNA composition that yields high levels of gene expression and
non-infectious HIV protein production, and induces a robust antibody
and cellular immune response in animal models, including non-human
primates.
The Company has completed a comprehensive non-clinical and clinical
development plan for GenePro™, and is advancing towards an IND.
The Company’s organizational structure consists of a highly qualified
and experienced team with complimentary expertise in clinical research,
biopharmaceutical development, strategic planning, finance, law, and
business operations. A Scientific Advisory Board and Board of
Directors comprise this team.
Back to the Top
Board of
Directors
James B. Laufenberg,
MBA,
is the President and CEO of ImmunoGenetix and a member of the board of
directors. Mr. Laufenberg has over 25 years in the pharmaceutical
and biotech industry. Most of his career was at Marion Laboratories (now Sanofi-Aventis), managing both
large organizations and small. During this tenure he accepted
increasing responsibilities, including management in a start-up
division. After leaving Marion, he joined Oxo Chemie as Vice
President of Marketing. Responsibilities included preparing the
company for the launch of an AIDS therapeutic, developing the label for
an NDA submission, and an interim period as CEO. His most recent
experience was as Vice President Sales and Marketing at Iomed, Inc.
Responsibilities included strategic planning with all functional heads,
integrating operational plans including regulatory and manufacturing,
and raising funds for product launch. Mr. Laufenberg has an MBA from
Rockhurst University.
Edward
M. Connolly, Jr., has more than 25 years’ experience in
corporate leadership. His background includes executive human resources
management for five major corporations where he advised senior
executives and directed compliance, labor relations, and associate
relations. His experience spans a broad range of business
environments including mergers, acquisitions, internal growth, and spin
offs. As President of corporate foundations, Ed’s strategic
philanthropic initiatives include building strong collaborations, among
the scientific, academic and business communities. He is affiliated
with Vistage International, Inc. the world’s largest CEO membership
organization, where he is Board Chair of a Vistage Group.
He serves on the Board of EPIQ Systems NASDAQ: ( EPIQ) and is also on
the Board of Children’s Mercy Hospital. He holds a B. A. in Psychology
from Bellarmine University.
William
J. Garner, M.D., has served as President and Chief Executive
Officer of Urigen since December 2005. Dr. Garner is an experienced
entrepreneur. Prior to founding Urigen, Dr. Garner had been the founder
and managing director of EGB Advisors, LLC, a pharmaceutical
commercialization boutique. Through this entity, Dr. Garner worked on a
number of biopharmaceutical business transactions and has raised
financing for another company that he founded called Inverseon, Inc.,
developing a novel therapy for asthma. Before this, Dr. Garner worked
in medical affairs at Hoffmann LaRoche in oncology. Prior to Roche, Dr.
Garner was in the venture capital department at Paramount Capital
Investments in New York City. Dr. Garner has a Master of Public Health
from Harvard and received his M.D. degree from New York Medical
College. Dr. Garner did residency training in Anatomic Pathology at
Columbia-Presbyterian and is currently a licensed physician in the
State of New York.
Ted
Knous, Ph.D. is Associate Vice Chancellor at the University of
Kansas Medical Center. Dr. Knous is responsible for
administrative oversight for the full range of pre- and post-award
services to facilitate the development, preparation, submission,
negotiation, and acceptance of proposals, contracts, and cooperative
agreements for extramural funding and ultimately ensure effective,
efficient and compliant management of federal, state, non-profit and
private funds. Dr. Knous received his Ph.D. in Plant Pathology from the
University of Minnesota in 1979. He has held numerous positions
at a number of academic institutions as a faculty researcher, an
assistant and associate dean for research and graduate studies, and as
an associate vice provost and associate vice chancellor for research
administration.
Edward
H. Stratemeier, J.D., MBA, is an attorney and consultant to the
life science industry. He was previously Senior Vice President of
Legal, Government Relations and Policy at Aventis Pharmaceuticals. His
extensive list of responsibilities included leading a team of over 40
lawyers in the United States, Canada, and Europe in general commercial
work, litigation, employment law, securities matters, business
development transactions, compliance, privacy and FDA regulatory
matters. His principal areas of focus are: Intellectual Property
Licenses and Litigation, Biosciences Commercialization, Government
Relations and Policy, and Strategic Alliances. Mr. Stratemeier earned
his J.D. at the University of Missouri Kansas City in 1973, an MBA at
Rockhurst University in 1990 and a BA at the University of Kansas in
1971.
David
L. Tousley, MBA, CPA, is currently Principal of Stratium
Consulting Services assisting companies with strategic and financial
planning and management, and brings an impressive list of professional
achievements in all aspects of financial, pharmaceutical development
and process management. Among his current clients is Deciphera
Pharmaceuticals, LLC, where he advises on and manages the financial
aspects of the business. Mr. Tousley has over 25 years of
business experience including biotech, specialty pharmaceuticals and
full phase pharmaceutical companies. He has held President, Chief
Operating Officer and Chief Financial Officer roles in companies such
as airPharma, LLC, PediaMed Pharmaceuticals, Inc., AVAX Technologies,
Inc. and Pasteur, Merieux, Connaught, (known today as Sanofi-Pasteur)
and has led companies in all aspects of operations, including
pharmaceutical development. He has managed in both the private and
public company environment, taking a company public, raising over
ninety million dollars in debt and equity financings and has led
business development activities, including joint ventures,
partnerships, acquisitions and divestitures in the U.S., Europe and
Australia. Mr. Tousley holds an undergraduate degree from Rutgers
College and earned his MBA in accounting from Rutgers Graduate School
of Business. Having earned his certification as a public accountant, he
belongs to the New Jersey Society of Certified Public Accountants and
the American Institute of Certified Public Accountants.
Back to the Top
Scientific
Advisory Board
Mike Beckloff, MS,
is President of Beckloff and Associates, a Cardinal health Company, and
has broad development experience working with regulatory agencies
worldwide, and maintains a network of recognized consultants and
experts. Mr. Beckloff has provided development support for formulations
ranging from solid dosage to sterile products, including AIDS drugs.
This broad knowledge base allows Mr. Beckloff to assist in the
strategic planning process in order to ensure fast and efficient
product development.
John
E. Dillberger, D.V.M., Ph.D. has spent more than 15 years in the
pharmaceutical industry, holding positions of increasing responsibility
at MMD, GlaxoSmithKline, Gilead (formerly Triangle) Pharmaceuticals,
and Charles River Laboratories. He currently has an active
practice as a Preclinical Development Consultant specializing in
pharmacology, toxicology, pathology, and biocompatibility. His
clients include nonprofit foundations and biopharmaceutical companies
in the United States, Korea, and Japan that are developing drugs,
biologics, and medical devices, as well as investment firms with
healthcare portfolios. Dr. Dillberger was certified as a
Veterinary Pathologist by the American College of Veterinary
Pathologists in 1987 and as a Toxicologist by the American Board of
Toxicology in 1992. He also is one of a handful of pathologists
accepted as a Fellow in the International Academy of Toxicologic
Pathology. He is the author of numerous scientific papers and a
book chapter entitled “Nonclinical Development of Drugs and Biologics:
Pharmacology and Toxicology,” serves as reviewer for Antimicrobial Agents and Chemotherapy,
and is presently serving a second term on the editorial board of Veterinary Pathology.
Gino
Girard, M.D. has been an independent medical consultant to the
pharmaceutical and biotech industries since 2000. He currently
provides consultation on the strategic planning and implementation of
clinical programs, investigator recruitment, protocol design, medical
monitoring, data analysis, clinical report presentation, IND and NDA
preparation, training of sales/marketing personnel, and is active in
forming pharmacovigilance programs for post marketing. He has
also served on various data monitoring committees. He is
specialized in internal medicine and infectious diseases,
board-certified in both with recent recertification (May 2002) in
internal medicine. He has experience in the development of
therapeutics in HIV, hepatitis, fungal disease, pneumonia,
endocarditis, skin and skin structure infections, Helicobacter pylori
infection, and Lyme disease. Dr. Girardi also has vaccine and
biologics experience. Beyond the area of infectious diseases, Dr.
Girardi has worked on numerous trials within the vast field of internal
medicine. Dr. Girardi received his B.A. in Biology from
Georgetown University in 1983 and M.D. from Georgetown in 1987.
He completed internal medicine residency at Georgetown University
Hospital where he was also appointed chief resident. He completed
fellowship in infectious diseases at the State University of New York
at Stony Brook in 1993. He spent one year in academic private
practice in Virginia before joining the Food and Drug Administration in
the Division of Anti-Infective Drug Products in CDER where he was a
medical officer from 1994-1998. He then joined Quintiles as
Senior Technical Director for Anti-infective therapeutics. In
2000, he became an independent consultant.
Michael
S. McGrath, M.D., Ph.D. is currently a Professor of Laboratory
Medicine, Medicine and Pathology at the University of California at San
Francisco (UCSF) with research laboratories located at San Francisco
General Hospital (SFGH). He received his MD from Stanford University in
1980 and his PhD in Cancer Biology from Stanford in 1985, and has
advanced medical training in the area of Hematology. Since 1985 he has
been the director of the AIDS Immunobiology Research Laboratory at UCSF
and his research activities have been concentrated in the area of HIV
pathogenesis. He has authored over 100 papers and 12 patents in
basic research areas involving HIV disease and cancer. Most recently
his research activities have been focused on the role that macrophages
play in the pathogenesis of chronic human disease. Drug and diagnostic
development programs involving aspects of this research have been
carried out with a variety of small biotechnology companies in which he
was either a co-founder or scientific advisor. He is currently
working with SLIL Biomedical, a Madison WI based biopharmaceutical
company that makes a class of drug that shows both anti-cancer and
anti-pathogenic macrophage activities in vitro and in vivo studies.
Back to the Top
Scientific
Collaboration
The Company has
exclusive world wide rights to the related DNA compositions invented at
the University of Kansas Medical center.
The
Marion Merrell Laboratory of Viral Pathogenesis at KU Medical
Center is currently staffed with approximately 20 scientists and
technicians, and is equipped with a P3 suite and the latest scientific
instrumentation and equipment to conduct all levels of SIV and HIV
research and preclinical development. The laboratory is a
multidisciplinary laboratory occupied by investigators with experience
in molecular biology, molecular virology, medical virology, tissue
culture operations involving virus cultivation and measurement,
immunology including antibody and cell-mediated immune studies,
flow-cytometry, histopathological, immunocytochemical, and
immunohisto¬chemical studies, and expertise in specific techniques
such as construction of DNA molecules intended as DNA vaccines,
evaluation of viral RNA expression in tissues by real-time RT PCR, in
situ hybridization and immunocytochemistry, and experience in animal
operations including inoculations, sampling of tissues, necropsies, and
evaluation of tissues from infected animals using virological,
pathological, immunological, and molecular (DNA/RNA) procedures.
Studies from this laboratory have yielded more than 200 peer-reviewed
publications and national and international recognition.
Back to the Top
|
|
